Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome Research Published on 2022-07-192022-10-05 Journal: Nature Communications [Category] 바이오마커, 임상, [키워드] antibody Antibody titer baseline binding booster vaccination clinical trial conducted coronavirus epitope Epitopes evaluate exploratory expressing homologous humoral responses identify IgG immunization immunogenic Increased magnitude MERS-CoV Middle East neutralization Neutralizing pandemic participant Phase 1 RBD respiratory syndrome coronavirus responses S2 subunit Safe spike glycoprotein Support syndrome the receptor-binding domain trial participant trials two-dose regimen vaccination vaccine candidate [DOI] 10.1038/s41467-022-31557-0 [Article Type] Research
Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccineMVA-MERS-S 백신으로 후기 3차 면역 후 MERS-CoV-스파이크 특이적 B 세포 및 항체의 지속성Article Published on 2022-07-192022-09-11 Journal: Cell Reports Medicine [Category] MERS, 임상, 진단, [키워드] Administered antibody antibody isotypes B cell B cell response B cells binding boost booster booster vaccination caused coronavirus Coronavirus 2019 COVID-19 Cytometry ELISA ELISPOT ENhance enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay enzyme-linked immunospot flow cytometry Frequency highlight homologous IgG IgG ELISpot IgG subclasses IgG1 immune immune persistence immune response immune responses Immunity immunization Immunoglobulin ImmunoSpot increase isotypes late booster vaccination long-term immunity longitudinal analysis memory B memory B cells MERS MERS coronavirus MERS-CoV MERS-S Middle East Middle East respiratory syndrome modified vaccinia virus MVA-MERS-S neutralization capacity neutralization test Neutralizing Neutralizing antibodies neutralizing antibody persistence Phase 1 phase 1 trial plaque-reduction neutralization test PRNT50 Protein respiratory Respiratory disease significantly Spike protein syndrome T and B cell responses T cell T cell responses Vaccination strategies Vaccine Viral Viral vector vaccine viral vector vaccine. [DOI] 10.1016/j.xcrm.2022.100685 PMC 바로가기 [Article Type] Article
A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primatesResearch article Published on 2022-07-012022-10-05 Journal: Vaccine [Category] 비임상, [키워드] aluminum Antibody Response asked B cell memory boost capsular catalyzed CD4 dose elicited Fever glutaraldehyde IgG IgG level IgG levels IgG response immune immunization IMPROVE induce lack mice NHP non-human primate overcome Phase 1 phosphate polysaccharide polysaccharide vaccine Protein repeated response robust Salmonella serum single dose stimulated subsequent sustained T cell Trial Vaccine vaccine candidate [DOI] 10.1016/j.vaccine.2022.06.043 [Article Type] Research article
Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: Evaluation of 5676 Phase 1 Passed Structures시험관내 항SARS-CoV-2 활성에 대한 고처리량 스크리닝 분석의 개발 및 최적화: 5676 1상 통과 구조 평가Clinical Trial Published on 2022-07-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus African green monkey anti-SARS-CoV-2 Anti-SARS-CoV-2 Activity Antiviral Antiviral agents Caco-2 can not cell lines Chloroquine clinical development clinical trials clinically Compound coronavirus coronavirus coronavirus disease Coronavirus disease 2019 coronavirus. COVID-19 COVID-19 pandemic COVID-19 treatment development Doxorubicin drug effective enhanced green fluorescent protein epithelial cell epithelial cells expressing fluorescent green fluorescent protein green monkey Hydroxychloroquine in vitro inhibitor inhibitors itraconazole kidney library nelfinavir outbreak pandemic pharmacokinetic data Phase 1 Protein Remdesivir SARS Coronavirus SARS-CoV-2 SARS-COV-2 infection strain Strains Structure Support these compound these compounds Toxicity Treatment Vaccine Vaccines VeroE6-eGFP cells virus was used [DOI] 10.1002/jmv.27683 PMC 바로가기 [Article Type] Clinical Trial
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial건강한 어린이에서 비활성화된 COVID-19 백신 WIBP-CorV의 안전성 및 면역원성: 무작위, 이중 맹검, 대조, 1/2상 시험의 중간 분석Clinical Trial Published on 2022-06-242022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] adverse events Adverse reaction Adverse reactions age alum Antibody Response assigned children China clinical trial Cohort cohorts conducted Controlled COVID-19 COVID-19 vaccine detectable dose dose-escalation double-blind effective vaccine Effective vaccines elicited Escalation Fever followed by geometric mean geometric mean titer geometric mean titers grade 3 groups healthy children Humoral response immunogenicity inactivated Inactivated vaccine injection injection site pain Interim Intramuscular injection Mild neutralizing antibody participant phase Phase 1 phase 1 trial Phase 2 phase 2 trial Placebo placebo-controlled Randomized Randomly ranged Registered robust Safe Safety safety profile Safety. SARS-CoV-2 significantly higher tested three group three groups vaccination Vaccine [DOI] 10.3389/fimmu.2022.898151 PMC 바로가기 [Article Type] Clinical Trial
Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 우려 변종에 대한 CpG-보강 S-2P 소단위 백신의 중화 능력 평가Article Published on 2022-06-102022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), MERS, SARS, 변종, 비임상, 진단, [키워드] Ability acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Against Alpha Alpha variant aluminum aluminum hydroxide antibody Antigen Beta Beta variant beta variants breath clinical trial coated with concern coronavirus coronavirus 2 COVID-19 CpG D614G demonstrated dose effective Effectiveness elicit elicited Evaluating High dose Human humans hydroxide immune response immunization immunized immunogenicity medium neutralization neutralization ability neutralization activity Neutralizing antibodies neutralizing antibody neutralizing capacity Neutralizing titer neutralizing titers Phase 1 prefusion pseudovirus pseudoviruses RAT RATs reduced reduction reduction in respiratory retained S-2P SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variant SARS-CoV-2 variants serum antibodies serum antibody serum sample serum samples severe acute respiratory syndrome Coronavirus significantly Spike protein subject subunit subunit SARS-CoV-2 vaccine the SARS-CoV-2 Vaccine Vaccines variant Variant of concern. variants VOCs wild-type [DOI] 10.1093/cid/ciab711 PMC 바로가기 [Article Type] Article
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label TrialSARS-CoV-2 DNA 백신 INO-4800, 1상 공개 라벨 시험에서 강화될 수 있는 내구성 면역 반응 유도Clinical Trial Published on 2022-06-012022-09-12 Journal: The Journal of Infectious Diseases [Category] Coronavirus, COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] activated acute respiratory syndrome Adults adverse event age Antibody Response Antigen being booster booster dose CD8+ T cell clinical clinical trial coronavirus coronavirus disease COVID-19 DNA DNA vaccine dosage dose effective Electroporation evaluated Frequency full-length healthy homologous immune response immune responses immunogenicity increase in INO-4800 intradermal injection Mild MOST pandemic Participants Phase 1 primary dose response Safe Safety. SARS-CoV-2 second dose Serious Adverse Events significantly increased subsequent Support T cell Trial Vaccine [DOI] 10.1093/infdis/jiac016 PMC 바로가기 [Article Type] Clinical Trial
Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19COVID-19에 대한 비강내 예방으로서 광범위한 변이 활성을 갖는 계란 유래 항-SARS-CoV-2 면역글로불린 Y(IgY)Clinical Trial Published on 2022-06-012022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 2019 novel coronavirus 2019-nCoV activity Administered Against Alpha anti-SARS-CoV-2 Antiviral approval approvals B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta binding capture chicken immunoglobulin clinical clinical trial clinical trial body Clinical use contagiousness Convalescent patients COVID-19 cross-reactivity Delta demonstrated develop Diseases distribution double-blind effective Emergency use authorization enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay Evidence evidence of greater healthy human tissue human tissues IgY Immunity immunized Immunoglobulin immunoglobulin Y index Infectious diseases infectious diseases. intranasal intranasally multiple dose multiple doses nasal drop nasal drops nasal mucosa neutralization titer no evidence of Novel coronavirus omicron Phase 1 phase 1 study Placebo placebo-controlled Prevalence Prophylaxis raised Randomized RATs RBD Receptor-binding domain reduce reduced risk Safe safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 strain SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 viral sensitivity sera Spike protein the receptor-binding domain the SARS-CoV-2 Tolerability Transmission Trial Vaccine Vaccine hesitancy variants variants of concern variety Viral virus [DOI] 10.3389/fimmu.2022.899617 PMC 바로가기 [Article Type] Clinical Trial
COVID-19 outbreak impact on health professionals: A survey on the Italian radiographer experienceResearch article Published on 2022-06-012022-10-05 Journal: Journal of medical imaging and radiation sciences [Category] COVID19(2023년), SARS, 진단, [키워드] Activation Computed tomography coronavirus COVID-19 COVID-19 outbreak COVID-19 positive patients diagnostic European country evaluate generate HCW Health high risk hospital Infection infection control involved Italian Italy majority management material men operator outbreak Patient patient safety performed Personal protective equipment Phase 1 PPE professional protocol Radiographers Radiography Radiological examinations Radiology Technologist Region responders Result Risk management SARS-CoV-2 serious infection Spread tomography worker X-ray X-ray computed [DOI] 10.1016/j.jmir.2022.02.006 [Article Type] Research article
Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial간질 세포 투여에 의한 급성 호흡 곤란 증후군의 회복(REALIST): 공개 라벨 용량 증량 1상 시험에 이어 무작위, 삼중 맹검, 할당 은폐, 위약 대조 2상 시험을 위한 구조화된 연구 프로토콜Article Published on 2022-05-132022-09-11 Journal: Trials [Category] COVID19(2023년), SARS, 임상, [키워드] 1:1 acute respiratory distress acute respiratory distress syndrome administration allocation ARDS benefit blind causes Cell cells clinical clinical trial Cohort cohort of patient cohorts of patients concealed CONSORT COVID-19 distress dose dose-escalation early stage early stages Efficacy EudraCT Good immunomodulatory incidence include Mesenchymal stem cells Mesenchymal stromal cell Mesenchymal stromal cells moderate to severe MSC MSCs multicentre NHS number Open-label outcome outlined oxygenation index patients patients with moderate Phase 1 phase 1 trial Phase 2 phase 2 trial Placebo placebo-controlled placebo-controlled trial Practice produced Protocol. randomised rationale receive recruited recruitment repair reported Reporting respiratory distress Respiratory distress syndrome Serious Adverse Events severe ARDS Standard stromal cell stromal cells Study protocol syndrome therapy Trial triple-blind umbilical Umbilical cord [DOI] 10.1186/s13063-022-06220-0 PMC 바로가기 [Article Type] Article